11 results about "Trichosanthin" patented technology

This invention discloses the application of plant extract saponins in aphid control and an aphidicide, belonging to the field of pesticides. This invention provides a novel plant-derived pesticide with aphid-killing activity, contributing to reducing aphid resistance and the use of chemical pesticides. Furthermore, the aphidicide prepared from plant extract saponins exhibits comparable aphid-killing efficacy to other commercial aphidicides, demonstrating broad development prospects and application value. It is an effective and feasible new aphidicide. Simultaneously, plant extract saponins are widely available and have a simple preparation process, which helps reduce the cost of aphidicides and facilitates widespread adoption.

The invention relates to the technical field of functional food processing, and discloses a medicated diet jasmine soft European and a making process thereof.The jasmine soft European is composed of dough and stuffing, and the dough is prepared from, by weight, 245-250 parts of high gluten flour; 40-50 parts of Chinese yam; 3-3.5 parts of dry yeast; 28 to 30 parts of berry sugar; 2-3 parts of salt; 100 to 105 parts of milk; 18 to 20 parts of butter; 45-50 parts of jasmine tea soup; the stuffing comprises the following materials in parts by weight: 500-505 parts of milk; 95 to 100 parts of cream cheese; 13 to 15 parts of jasmine tea powder; 180 to 200 parts of kasaka powder; 5-8 parts of radix trichosanthis; 10-15 parts of snow pears; the preparation method comprises the following steps: softening the butter at room temperature, steaming and mashing the Chinese yam, soaking the jasmine tea into tea soup according to a ratio of 1: 2 for later use, mixing with other materials to prepare dough, refrigerating, adding the butter and the salt, kneading until a film is formed, performing primary fermentation, uniformly mixing and stirring the stuffing materials, refrigerating and shaping, exhausting, cutting and loosening the dough after the fermentation is completed, and performing secondary fermentation. And finally, fermenting for the second time, and baking until the surface is golden yellow, thereby obtaining the medicated diet jasmine soft rice.

The invention provides a pharmaceutical composition for treating radiation-induced oral mucositis, which comprises two dosage forms, namely decoction and powder, the decoction is prepared from the following raw materials in parts by weight: 10-30 parts of radix rehmanniae, 9-20 parts of radix scrophulariae, 10-20 parts of radix ophiopogonis, 10-20 parts of moutan bark, 10-30 parts of honeysuckle, 5-20 parts of fructus forsythiae, 9-20 parts of scutellaria baicalensis, 9-15 parts of platycodon grandiflorum, 5-15 parts of oroxylum indicum and 10-20 parts of blackberry lily. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-30 parts of radix adenophorae, 10-20 parts of radix polygonati officinalis, 10-20 parts of radix trichosanthis, 20-50 parts of radix astragali, 10-30 parts of roasted rhizoma atractylodis macrocephalae, 9-15 parts of liquorice root, 10-30 parts of roasted malt and 10-30 parts of roasted fructus oryzae germinatus. The powder is prepared from the following raw materials in parts by weight: 0.15 to 0.5 part of calculus bovis cultured in vitro and 0.15 to 0.5 part of pearl powder; the decoction is orally taken after being decocted. The powder is blown into the diseased part of the oral cavity of a patient. According to the medicine composition, the whole body of a patient is conditioned from the basic pathogenesis of radiation-induced oral mucositis by adopting decoction oral administration, so that the effects of removing heat to cool blood, detoxifying, relieving sore throat, nourishing yin and promoting salivation are achieved; the powder is directly administered to a lesion part, so that the effects of clearing away heat and toxic materials, relieving swelling and pain, healing sore and promoting tissue regeneration are enhanced.

The present invention discloses a novel trichosanthes fusion protein. Specifically, the present invention modifies the trichosanthes protein with poor intracellular performance, fuses the transmembrane protein and the matrix metalloproteinase substrate domain, and utilizes the self-cleavage mediated by the intein to obtain a high-specificity low-immune prototype tumor-suppressive trichosanthes fusion protein that is easy to PEGylate and very conducive to intracellular entry. The present invention not only provides a new method for mediating the intracellular entry of trichosanthes protein, but also opens up new ideas for the new use of traditional Chinese medicine.

The invention discloses application of radix trichosanthis polysaccharide to preparation of a medicine for regulating immunity and inhibiting postoperative recurrence of colorectal cancer. The radix trichosanthis polysaccharide is found to be capable of promoting M2 phenotype macrophages to be polarized to M1 phenotype, and has an immunoregulation function; meanwhile, proliferation of peripheral blood lymphocytes and spleen lymphocytes is promoted, the proportion of CD4 +, CD8 + and NK cells is increased, and the effect of enhancing immunity is achieved. Furthermore, the hydrogel CMOT prepared by taking the radix trichosanthis polysaccharide as the raw material has good biocompatibility in vitro and in vivo and has the qualified characteristic of hydrogel, and the CMOT hydrogel is found to have the effect of inhibiting the recurrence of the colorectal cancer when being applied to the resection part of the mouse colorectal cancer operation. Therefore, the radix trichosanthis polysaccharide hydrogel has the potential of becoming a postoperative wound dressing after cancer resection.

The invention discloses a coccidoxane sesquiterpene CNA as well as a preparation method and application thereof, and belongs to the field of traditional Chinese medicine preparation. According to the present invention, cold soaking, silica gel and gel column chromatography are adopted to separate and extract the cocculin type sesquiterpene CNA compound represented by a formula I from coriaria sinica linn; the CNA compound has a novel cis-hydrogenated indene core structure, contains nine continuous chiral centers, has the characteristic of a highly crowded polycyclic skeleton, and has good biological activity. Cell experiments show that the coccidoxane sesquiterpene CNA can inhibit signal transduction of GABAB receptors in endogenous and exogenous systems, and can be used for preparing drugs for treating or preventing nervous system related diseases. A new direction is opened up for developing novel GABAB receptor antagonists or modulators, exploring GABA receptor related therapeutic targets and developing nervous system disease drugs.

The invention relates to the field of medical biological materials, and particularly discloses injection gel for repairing postpartum uterus scar diverticulum and a preparation method of the injection gel. The invention discloses injection gel for repairing postpartum uterus scar diverticulum. The injection gel is prepared from 20 to 30 parts of PDLLA-PEG-PDLLA hydrogel, 0.5 to 1 part of human umbilical cord mesenchymal stem cells, 0.3 to 0.8 part of trichosanthin nanoparticles and 0.1 to 1.2 parts of keratinocyte growth factors. The injection gel can be used for treating the uterine scars, and a more feasible treatment method is provided for the cure rate and the pregnancy rate of patients with the uterine scars clinically.

The invention provides a radix trichosanthis fusion protein, nanoparticles formed by self-assembly of the radix trichosanthis fusion protein, and a preparation method and application of the nanoparticles. The radix trichosanthis fusion protein and the self-assembled nanoparticles thereof can accurately target tumor cells and tissues, so that tumors can be efficiently and accurately killed, and meanwhile, the radix trichosanthis fusion protein and the self-assembled nanoparticles have almost no influence on normal cells and tissues and show extremely high selectivity. Therefore, the Mongolian snakegourd root fusion protein and the nanoparticles formed by self-assembly of the Mongolian snakegourd root fusion protein provided by the invention not only show an excellent tumor killing effect, but also have no obvious side effects, provide safe and effective treatment choices for tumor patients, and have relatively high clinical application prospects and values.

The present application relates to genetic engineering and relates to a trichosanthin trypsin inhibitor gene SsBBI and SsBBI3 gene and its encoded product and application SsBBI3 The nucleotide sequence of the gene is shown as SEQ ID NO. 1, the amino acid sequence of the encoded product is shown as SEQ ID NO. 2, and the trichosanthin trypsin inhibitor protein SsBBI3 is obtained by cloning, amplification and expression in engineering bacteria of the trichosanthin trypsin inhibitor gene SsBBI3 The protein is modified from the trichosanthin trypsin inhibitor protein SsBBI, and the modification method is to cut off the intramembrane region and the transmembrane region of SsBBI and retain the extramembrane region. The nucleotide sequence of the SsBBI protein is shown as SEQ ID NO. 3, and the amino acid sequence of the encoded product is shown as SEQ ID NO. 4. This trichosanthin trypsin inhibitor has the effect of significantly inhibiting tumor cell proliferation at a low dose, and has good application prospect.

The invention belongs to the technical field of biotechnology, traditional Chinese medicine modernization and functional food, and provides a trichosanthes root protease hydrolysate, a preparation method and application thereof.The preparation method adopts phosphate buffer solution low-temperature extraction to help maintain protein activity and reduce denaturation loss, ammonium sulfate fractional precipitation and blue agarose gel affinity chromatography are combined, and the content of trichosanthes root protease hydrolysate is increased. The target protein can be efficiently purified, and a high-purity reaction substrate is provided for subsequent enzymolysis, so that the uniformity and activity stability of a final product are improved. In the two-step composite enzymolysis step, directional shearing of protein is realized by accurately controlling the ratio of alkaline protease to trypsin, the action pH value, the temperature and the time, so that not only can the generation of small molecular peptide fragments be promoted, but also the molecular weight distribution of the product can be improved, the proportion of high-activity components less than 1kDa is remarkably increased, and the yield of the product is improved. The solubility and the oral absorption efficiency are enhanced. The preparation method disclosed by the invention is mild in condition, clear in operation parameter, good in repeatability and easy for large-scale amplification.

This invention discloses a triptolide sustained-release injection, its preparation method, and its application, belonging to the field of pharmaceutical technology. The sustained-release injection is composed of triptolide-polylactic acid-glycolic acid copolymer nanoparticles and hyaluronic acid hydrogel. The triptolide-polylactic acid-glycolic acid copolymer nanoparticles are prepared by a double emulsion-solvent evaporation method, with an encapsulation efficiency of 60.58±0.91% and a drug loading of 1.16±0.13%. The nanoparticles are further encapsulated in the hyaluronic acid hydrogel to form a composite formulation with good injectability. This invention also provides a method for establishing a collagen-induced arthritis (CIA) model in mice. By administering the drug via local intra-articular injection, a dual sustained-release effect is achieved, significantly reducing the systemic toxicity of triptolide, alleviating paw swelling, improving knee joint pathological changes, regulating serum inflammatory factor levels, and reducing liver and spleen damage in the model mice. This triptolide sustained-release injection has broad prospects for application in the preparation of drugs for treating rheumatoid arthritis.